State

State is a biotechnology company focused on developing a new class of medicines that target state-dependent biology, particularly within ion channels and transporters. By leveraging advanced screening technologies and structural biology, the company aims to identify small molecules that bind to specific functional states of proteins, potentially offering higher selectivity and reduced side effects compared to traditional inhibitors. The company's primary focus is on addressing high-value targets in neurology and other therapeutic areas where conventional drug discovery has faced challenges. State is currently in the pre-clinical stage, building a pipeline of precision therapies for complex diseases.